4/16/2009

MedImmune Showcases Commitment to Cancer Research at Annual Meeting of the American Association for Cancer Research

Tags:

GAITHERSBURG, MD, April 16, 2009 — MedImmune today announced that a dozen abstracts on progress being made in various oncology programs will be presented during the Annual Meeting of the American Association for Cancer Research in Denver, Colorado from April 18 to 22.

Cancer research has long been a core area of focus at MedImmune and we are proud to share data from our increasingly broad oncology portfolio at this year’s meeting, said Bahija Jallal, Ph.D., senior vice president, research. MedImmune research scheduled to be presented includes:

  • Identification of a human antibody 3.19.3 that inhibits ANG-2 function leading to significant anti-tumor activity in a panel of tumor xenograft models (Poster Session: Tumor Biology 1, abstract 137, poster section 5, board 23 ) — Sunday, April 19 from 8:00 a.m. — 12:00 p.m. in Exhibit Hall B-F.
  • Anti-tumor efficacy of the 3.19.3 ANG-2 antibody in combination with VEGF inhibitors in tumor xenograft models (Poster Session: Tumor Biology 1, abstract 127, poster section 5, board 5) —Sunday, April 19 from 8:00 a.m. — 12:00 p.m. in Exhibit Hall B-F.
  • Novel antibodies to erbB2 which inhibit the growth of tumor cell lines expressing varying levels of receptor (Poster Session: Experimental and Molecular Therapeutics 2, abstract 831, poster section 36, board 36) — Sunday, April 19 from 8:00 a.m. — 12:00 p.m. in Exhibit Hall B-F.
  • A fully human antibody that inhibits the integrin avb6 reduces tumor growth and modulates key biomarkers (Poster Session: Experimental and Molecular Therapeutics 2, abstract 847, poster section 36, board 36) — Sunday, April 19 from 8:00 a.m. — 12:00 p.m. in Exhibit Hall B-F.
  • Inhibition of VEGFR2 dimerisation, a novel mechanism of inhibiting VEGFR2 signaling (Oral Presentation: Tumor Biology 16, abstract 1997) —Monday, April 20 9:30 a.m. — 1:00 p.m. Room 402 — 404, Colorado Convention Center.
  • MEDI3617, a fully human anti-angiopoietin 2 monoclonal antibody, demonstrates inhibition and tolerability alone and in combination with chemotherapy in xenograft models (Poster Session: Experimental and Molecular Therapeutics 14, abstract 2793, poster section 32, board 23) — Monday, April 20 from 1:00 p.m. — 5:00 p.m. in Exhibit Hall B-F.
  • Isolation of novel functional anticancer antibodies by phage display. (Poster Session: Experimental and Molecular Therapeutics 17, abstract 2876, poster section 35, board 20) — Monday, April 20 from 1:00 p.m. — 5:00 p.m. in Exhibit Hall B-F.
  • MEDI-573: A fully human antibody to IGF-I and IGF-II for the treatment of solid tumor and hematological diseases (Poster Session: Experimental and Molecular Therapeutics 15, abstract 2802, poster section 33, board 2) — Monday, April 20 from 1:00 p.m. — 5:00 p.m. in Exhibit Hall B-F.
  • In vivo pharmacology of MEDI-573, an anti-IGF-I and IGF-II antibody that targets the IGF-1R and IR-A signaling pathways (Poster Session: Experimental and Molecular Therapeutics 15, abstract 2803, poster section 33, board 3) — Monday, April 20 from 1:00 p.m. — 5:00 p.m. in Exhibit Hall B-F.
  • In vitro pharmacological comparison of a CEA/CD3 bispecific cynomolgus-reactive biosimilar BiTE antibody (cyS111) with the clinical candidate MEDI-565 (MT111). (Poster Session: Immunology 5, abstract 3247, poster section 12, board 15) — Tuesday, April 21 from 8:00 a.m. — 12:00 p.m. in Exhibit Hall B-F.
  • EphB4 inhibits HUVEC cell growth through suppression of the Ras/MAPK pathway. (Poster Session: Cellular and Molecular Biology 54, abstract 4383, poster section 23, board 10) — Tuesday, April 21 from 1:00 p.m. — 5:00 p.m. in Exhibit Hall B-F.
  • A fully human antibody inhibits urokinase receptor function in vitro. (Poster Session: Tumor Biology 27, abstract 3091, poster section 6, board 4) — Tuesday, April 21 from 8:00 a.m. — 12:00 p.m. in Exhibit Hall B-F.

About MedImmune
MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,100 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, we aim to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health. For more information, visit MedImmune’s website at www.medimmune.com.

Contacts:
Media: Sidoney Atsé, 301-398-5990

http://www.medimmune.com